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Abstract
What is known and objective: Polypharmacy is common, and many medications have 
cognitive side effects. Such effects can be transient and subside when the drug in 
question is discontinued or can be long-lasting with effects present for years after-
wards. Although formal assessment of cognition is feasible and often undertaken in 
neuropsychiatric trials, these effects are usually neglected in the evaluation of any 
non-neuropsychiatric health intervention. Medication effects can be assessed within a 
cognitive footprint framework, to account for the magnitude and the duration of cogni-
tive side effects, with some likely to have a greater and more lasting effect than others.
Comment: Adverse event reporting suggests that many medications may be indi-
rectly associated with cognitive effects, for example due to headaches, somnolence 
and ‘dizziness’; however, inferring causation from adverse event reporting can be 
problematic. In order to better understand the impact of investigational drug and 
concomitant medications effect on cognition, it would be essential to ensure cogni-
tion is prioritized in drug development evaluation. It is suggested that simple instru-
ments that can be easily incorporated into existing trial designs are used to assess the 
cognitive footprint of medication.
What is new and conclusion: We present an overview of existing measures of cognition 
that can be integrated into drug trials in order to provide a cognitive footprint. Like quality 
of life testing, such tests should be administered as a standard throughout the key assess-
ment stages of the design of the trial to ensure that any effects on this equally important 
outcome are also documented. Furthermore, employing routine cognition testing may 
also enable researchers to identify unanticipated beneficial and non-beneficial effects on 
cognition. Provision of such a cognitive footprint profile of drugs may provide the nec-
essary evidence to enable decision-makers to make informed decisions on risk-benefit 
analysis that can subsequently make trade-offs between different drug regimens.
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1  | WHAT IS KNOWN AND OBJEC TIVE
Many medications are associated with significant cognitive effects; 
these cognitive effects are often under-reported, rarely measured 
in Phase III trials and consequently rarely considered in doctors' 
and patients' choices between different drug regimens. This neglect 
of cognition not only hinders informed decision-making but it also 
misses an important opportunity not only to identify negative ef-
fects but also to identify whether medications have a positive effect 
where cognition is not the primary outcome of interest. Cognitive 
effect can be on target beneficial effects, for example anticholin-
esterase inhibitors prescribed for people with Alzheimer's disease,1 
or off-target negative effect such as neurodevelopmental delay in 
offspring following sodium valproate use by pregnant women.2 In 
addition, medications are commonly prescribed, with 18.6 items pre-
scribed per head in England in 2015.3 This number increases in those 
over the age of 65 years. Polypharmacy (5-8 prescribed medications) 
and excessive polypharmacy (≥9 prescribed medications) can be 
particularly problematic for older adults, with both associated with 
poorer cognitive ability.4
Medications can have direct effects on cognition; for example, 
anticholinergic burden in geriatric inpatients is independently as-
sociated with cognitive impairment.5 However, medication can also 
have indirect consequences for cognition, with dizziness, headaches, 
somnolence and fatigue all having the potential to impair cognitive 
function. Headaches, a commonly reported side effect of medica-
tion,6 are associated with abnormalities in memory, attention and 
information processing speed.7
Medications can exert a cognitive effect at any time across the 
lifespan, for example the effect of sodium valproate in utero, and the 
association of an increased risk for cerebral palsy and neurodevel-
opmental delay with postnatal steroid therapy in early infancy.8 In 
children, some noradrenaline reuptake inhibitors (NRI) are effective 
for cognitive and behavioural symptoms of attention deficit hyper-
activity disorder (ADHD), but are associated with potential cogni-
tive adverse events such as somnolence, dizziness and fatigue.9 In 
adulthood, chemotherapy is associated with self-reported cognitive 
impairment, sometimes called ‘chemobrain’ or ‘chemofog’,10 and 
fatigue can be a common adverse event.11 Triptans including zol-
mitriptan are increasingly prescribed for migraines, but the bene-
fit of headache abortion should be evaluated in the context of an 
increased risk of cognitive adverse events including dizziness and 
somnolence.12 For older adults, antimuscarinics can be prescribed to 
treat urge incontinence or nocturia but are also associated with an 
increased risk of cognitive decline.13
Cognitive side effects can be long-lasting and have serious im-
plications for health and well-being. For example, ‘chemobrain’ has 
been reported to last up to 20 years following adjuvant chemother-
apy,14 and some medications appear to increase the risk of later 
dementia. In particular, medications with an anticholinergic burden 
score of three are associated with an increased risk of a dementia 
diagnosis 15-20 years later (RR 1.11; 95% CI 1.08 to 1.14).5 Further, 
there is often disparity between clinical and statistical significance 
for adverse effects and the current configuration of clinical trials 
limits the degree to which both clinical significance and delayed ad-
verse events can be accurately captured. This is particularly rele-
vant for very rare cognitive effects classed by the British National 
Formulary as 1 in 10 000 to 1 in 1000. Such effects are unlikely 
to be captured in Phase III trials but may be captured in Phase IV 
postmarketing surveillance studies. However, the reporting of these 
cognitive effects can be reliant on voluntary reporting schemes such 
as the Yellow Card Scheme.15
However, the majority of cognitive effects are transient, for ex-
ample a drug-induced headache16 or adverse events such as som-
nolence or dizziness. These effects will generally subside after a 
medication is discontinued but, while being prescribed, any benefit 
to the primary condition should be evaluated in the context of this 
potential adverse effect. Furthermore, although the effects of med-
ication may be transient, when they occur in large groups of people 
they nonetheless generate a large aggregate burden, both in terms 
of health as in indirect effects on productivity, disturbed daily activ-
ities, etc Moreover, although the cognitive effects can be transient, 
their long-term consequences in terms of human capital acquisition 
may nevertheless be permanent, such as reduced educational op-
portunities or career interruptions and ultimately societal impact.
We argue that in addition to the usual outcomes on which med-
ications are typically tested, they should also be evaluated in terms 
of their specific cognitive impact. This approach to medication ef-
fects can be conceptualized within a ‘cognitive footprint’ framework 
that assesses not only the size of an effect but also the duration.17 
Although cognition is more complex to evaluate than usual out-
comes, there are reliable and meaningful resources available to re-
searchers aiming to do so. In this article, we provide an overview of 
available measures that can be used to assess the cognitive effects 
of drugs. We first discuss the various available cognition measures in 
the neuropsychiatry and paediatrics domain, and then, we assess the 
usefulness of adverse events reporting.
2  | COMMENT
2.1 | Measuring cognition
The standardized measurement of cognition in CTIMPS is usually 
within a deficit paradigm, with the focus on measures of cognitive 
impairment. Thus, the standardized measurement of cognition is 
usually only employed in samples where there is pre-existing cog-
nitive impairment, such as in dementia research, and where cogni-
tive impairment is of importance from a developmental perspective, 
as in childhood studies.18 Outside of these populations, cognition 
is usually not measured as standard in clinical trials. This stands in 
contrast to health-related quality of life (HRQoL), which has gained 
much traction in recent decades and is now almost universally meas-
ured in health research.19 With the development of health technol-
ogy assessment and cost-effectiveness analysis based on health 
outcome measures such as quality- or disability-adjusted life years 
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as currencies to measure the health gains of drugs, surveys that 
monitor the HRQoL are routinely taken from patients. Standard sur-
veys such as the EuroQoL or SF-6D predominantly focus on physical 
health impacts and incorporate only very narrow mental outcomes. 
For instance, the EuroQoL assesses impacts on anxiety and depres-
sion and the SF-6D assesses vitality and whether someone feels 
downhearted. But cognitive effects are excluded and hence not con-
sidered part of HRQoL. This exclusion not only has implications for 
the assessment of the effectiveness of drugs but it also influences 
resource allocation decisions. Patient access to medical products is 
optimal when the right patient receives the right medication at the 
right time in-line with the WHO Sustainable Development Goals. 
Moreover, the neglect of cognition misses an important opportunity 
to identify negative effects but also to identify whether medications 
have a positive effect where cognition is not the primary outcome 
of interest.
2.1.1 | Neuropsychiatric cognition measures
Some of the more commonly measures are discussed below, but 
more comprehensive lists were beyond the scope of the current 
manuscript and are covered by other reviews.20
The most well-known cognition measure for people with 
Alzheimer's disease or other dementias is the Mini-Mental State 
Examination (MMSE).21 It is widely used and has been translated 
into at least 15 other languages.22 However, the MMSE23 is less able 
to accurately capture milder forms of cognitive impairment such as 
those related to age.24 It also has low sensitivity when used among 
individuals with general neurological and psychiatric conditions.25 In 
practice, the MMSE is also heavily weighted towards literacy skills, 
with significant correlations noted to be higher for literacy level than 
other demographic variables.26
Other measures used to screen for cognitive impairment include 
the Montreal Cognitive Assessment (MoCA),27 the Alzheimer's 
Disease Assessment Scale Cognitive Subscale (ADAS-Cog),28 the 
Addenbrooke's Cognitive Examination (ACE-III),29 the Cambridge 
Cognitive Examination (CAMCOG),30 the Saint Louis University 
Mental State Examination (SLUMS),31 the General Practitioner 
Assessment of Cognition (GPCOG),32 the Mini-Cog33 and the 
Abbreviated Mental Test (AMT).34 Of these measures, the MoCA 
has been increasingly used, potentially due to its increased sensi-
tivity for mild cognitive impairment, compared with the MMSE.27 
Furthermore, the MoCA has also been applied in a range of pop-
ulations including cancer,35 diabetes,36 famine37 and epilepsy.38 
However, most of the dementia-specific screening tools are subject 
to limitations, including ceiling effects when used in other popula-
tions. For example, it has been suggested that the ADAS-Cog relies 
overly on memory testing39 and the reliability of the AMT has been 
questioned with 80% of junior doctors in one study failing to use the 
test accurately.40
Cognition testing is used frequently for people with a diagnosis of 
schizophrenia. The Brief Assessment of Cognition in Schizophrenia 
(BACS) is a composite measure of existing cognitive tests designed 
to assess impairment in verbal memory, working memory, motor 
speed, verbal fluency, attention and speed of information process-
ing and executive function.41 The BACS was specifically developed 
for people with schizophrenia with a focus on the aspects of cog-
nition found to most be impaired in this population. While it has 
been validated in some other populations such as older adults with 
bipolar disorder,42 it may hold less validity for clinical populations. 
The Measurement and Treatment Research to Improve Cognition 
in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) 
was also developed to assess the clinical effectiveness of medica-
tion, cognitive remediation among adults with schizophrenia and 
to provide a reference point for non-intervention studies of schizo-
phrenia.43 Like the BACS, the MCCB is focused primarily on specific 
deficits associated with schizophrenia including social cognition. An 
assessment of the relevance of the MCCB for bipolar populations 
concluded that the deficits measured by the MCCB were weighted 
towards more severe impairment than was needed for a bipolar pop-
ulation; it was thus suggested that different sub-tests were more 
appropriate.44
Other neuropsychiatric populations for which cognition testing 
is becoming increasingly common are those of major depressive 
disorder (MDD) and bipolar disorder. However, this field is limited 
due to the subjective nature of assessments used and a bias towards 
negative cognitive schemas.45 This limitation is apparent in analy-
ses of the Massachusetts General Hospital Cognitive and Physical 
Functioning Questionnaire (CPFQ), in which no correlation was 
found between self-reported cognitive difficulties on the CPFQ and 
a clinician-administered instrument of cognition.46
2.1.2 | Paediatric cognition measures
Clinical paediatric cognition measures are employed for diagnosis, 
screening, research, programme evaluation and intervention plan-
ning.18 The measures are often set within classic psychological 
frameworks such as Piaget's four stages of cognitive development, 
namely sensorimotor, preoperational, concrete operational and for-
mal operational.47 Some measures that are not appropriate for an 
adult population, for example the Bayley Scales of Infant and Toddler 
Development—Third Edition (BSID-III),48 are not discussed here.
Measures of attention and executive functioning may pro-
vide valuable indications of impairment secondary to drug effects. 
Conners' Continuous Performance Task-II (CPT II) is a measure 
of sustained and selective attention49 as is the Trail Making Test 
(TMT).50 In a review, both measures were determined to be ap-
proaching ‘well-established’ criteria, with favourable psychometric 
properties in samples of children with attention deficit hyperactivity 
disorder (ADHD).51 However, reviewers noted that the test-retest 
reliability of the CPT II was variable ranging from 0.5 to 0.92 and 
that both measures are used within a diagnostic framework, where 
the aim is to distinguish non-impaired controls from individuals with 
neurological or learning impairments. Moreover, adult studies of the 
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CPT II are mainly limited to adults with a traumatic brain injury,52 
limiting its usefulness outside of these settings. The TMT has also 
been used in adult settings (18-89 years of age), with normative data 
stratified by age group and education.53 Results suggest that age 
accounts for more variance on both Trails A and B (34% and 38%), 
while education accounts for less variance (3% and 6%) allowing 
for a comparison of cognitive function while controlling for varying 
ages and education. As such, the TMT may be an appropriate tool to 
measure the cognitive effects of medications for both paediatric and 
healthy populations.
2.1.3 | Adverse event reporting
Outside of neurological and psychiatric trials, cognitive meas-
urement and consequently cognitive assessment are rarely per-
formed. However, one way to evaluate potential cognitive effects 
of medication is to examine adverse events. Safety reporting is 
mandatory in trials of medication and is classified as adverse event/ 
reaction (AE/AR), serious adverse event/ reaction (SAE/SAR) or a 
suspected unexpected serious adverse reaction (SUSAR). All clini-
cal trials of an investigational medicinal product (CTIMPs) are re-
quired to collect information regarded as critical to the evaluation 
of the safety of a medicinal product and report this information 
to a study sponsor. However, only SAEs and SUSARs need to be 
reported to the sponsor and in some cases the relevant Research 
Ethics Committee (REC).54
Current MEDRA classification system may enable cognitive 
signals to emerge but determining what constitutes a cognitive 
AE can be problematic, with dizziness, insomnia, somnolence, 
headaches and fatigue all having the ability to impair cognition. 
Data on medication-induced cognitive adverse events are sparse 
and are usually limited to specific reactions. However, there are 
several problems. First, what data are available suggest that cog-
nitive adverse events are under-reported and under-researched. 
For example, headache is a frequently reported adverse event 
implicated in a range of medications,55 and the use of opioid an-
algesics can increase incidence of somnolence and dizziness.56 
Second, the impact of these events can be difficult to determine, 
with statistical testing used variably. In some cases, only percent-
ages of participants reporting adverse events in both the active 
and the control groups are described, and no formal analysis is 
undertaken of the effects size. Third, drowsiness, nausea, fatigue, 
headache and insomnia are often reported as a nocebo effect,57 
which can confound such results.58 Fourth, observable outcomes 
related to these events are lacking and the relationship between 
multiple adverse cognitive effects is likely to be complicated. This 
relationship may consist of trade-offs where, for example, a pos-
itive effect on cognition from reducing pain may also have a neg-
ative effect on cognition by increasing drowsiness or sedation.59 
However, the use of AEs as a cognitive surrogate is inadequate and 
so cognitive measures are needed.
2.2 | Scalable measures of cognition in trials
Given the limitations associated with AE reporting, measures of at-
tention may give an indication of overall cognitive impairment and 
enhancement perspective, but are also sensitive to specific cogni-
tive domains such as executive function and processing speed. The 
Deary-Liewald Reaction Time task (DLRT) is a freely available meas-
ure of reaction and choice reaction time. Preliminary psychometric 
properties of the DLRT are promising, with excellent internal con-
sistency and observed, expected correlations with age. However, it 
should be noted that the choice reaction time section of the test had 
more robust psychometric properties.60 Furthermore, more empiri-
cal investigations of the DLRT are needed to further determine its 
ability to detect cognitive change.
The Stroop test measures the executive requirement to screen 
out distracting information, for example the challenge of calling out 
the colour in which a word is printed when this is incongruent with 
what the word says (eg blue written in a red font).61 Since its in-
ception in 1935, numerous researchers have published studies and 
reviews exploring the effect in a range of populations including ad-
olescents with ADHD,62 young adults, older adults and people with 
Alzheimer's Disease.63 Within the latter study, the Stroop test was 
sensitive to age effects with authors attributing the decline in per-
formance to the loss of inhibitory processing. As an indication of 
intraindividual cognitive fluctuation, or the degree to which cogni-
tion fluctuates from baseline to follow up within persons, the Stroop 
may be a useful tool for the cognitive footprint of a medication. 
Furthermore, the Stroop test can be visualized as on a spectrum, 
with no established criteria separating clinically impaired from un-
impaired. It may, therefore, also be appropriate to assess sub-clinical 
levels of impairment or enhancement across a range of medications 
and may be a means of evaluating the observable impact of side ef-
fects such somnolence or headaches on cognition.
In terms of more detailed assessment, Cambridge Cognition has 
developed two computerized systems to address the lack of observ-
able outcomes associated with drug-induced cognitive impairment. 
Named the Clinical Trial Information System-Profile (CTIS-Profile) 
and Clinical Trial Information System-Profile 2+ (CTIS-Profile 2+), the 
systems incorporate measures of processing speed, sustained atten-
tion, working memory, visual episodic memory and executive func-
tion to determine whether medications are implicated in observable 
cognitive impairment. The CTIS measures are rigorous and primarily 
designed for use in CTIMPs. However, associated costs and time to 
complete may limit use outside of formal trials or across disciplines.
3  | WHAT IS NE W AND CONCLUSION
Cognition is a fundamental aspect of life, allowing individuals to 
function fully as individuals and as members of a society. The neglect 
of cognitive testing as routine may be due to a pervading viewpoint 
that cognition is only relevant for populations such as those with 
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Alzheimer's disease and evidenced by the abundance of cognition 
measures developed for these populations. The cognitive footprint 
is a theoretical framework in which cognition is viewed as a vital 
outcome across the lifespan that significantly influences the health, 
social and economic state of individuals and that deserves to be in-
cluded in any drug, health or broader policy evaluation. Furthermore, 
cognition is conceptualized as a broad spectrum of abilities, with fac-
tors at different ages exerting transient or long-lasting effects on 
function. Such factors may enhance or impair cognition and summate 
in determining the cognitive capabilities of individuals or societies.
However, as reviewed here, measures of cognition used in tri-
als are measures of cognitive impairment developed from a deficit 
standpoint, with ceiling effects evident for clinically non-impaired 
populations. This misses an important opportunity to identify the 
cognitive effects of a range of medications in trials beyond those 
with neuropsychiatric outcomes Thus, current measures of cogni-
tion are not suitable for assessing different cognitive footprints. 
Further, each measure identified would need to be subject to a psy-
chometric appraisal to ensure it remains a valid and reliable tool to 
measure cognitive change in each population in which it is employed.
With regard to assessing the cognitive footprint of medications, 
adverse event reporting suggests that many drugs have cognitive ad-
verse effects that may be mediated through non-specific symptoms 
such as dizziness, somnolence and headaches. However, using ad-
verse event reporting to ascertain cognitive effects is problematic, 
and cognitive symptoms are usually not given weight, with medica-
tions implicated described as well-tolerated.64 While the acceptabil-
ity of these symptoms is likely to be very variable, with patients able 
to tolerate differing levels of cognitive symptoms, the importance of 
these effects for quality of life of activities of daily living can be un-
derestimated. Furthermore, there have been no formal examinations 
of the association between these adverse events and standardized 
measures of cognition. As such the degree to which, for example, 
medication-induced somnolence affects cognition as assessed using 
outcome measurement is currently unknown. The physical exam-
ination in trials is conducted regularly and to a standard format and 
would benefit from the addition of a cognitive module. We suggest 
that measures of cognition such as the Stroop test or the DLRT may 
be an appropriate means of assessing cognitive effects of medica-
tions. Such tests are often easy to administer, with short completion 
times, minimal training required and they can be easily utilized out-
side the clinical context. Compared with systems such as CTIS, these 
tests are also in the public domain, which is in-line with Open Science 
principles and allows for their uptake across disciplines with minimal 
associated costs. Incorporating these tests as standard in both clin-
ical practice and research will ensure that the cognitive impact of a 
wide range of medications can be formally examined, assessed and 
actioned where required at the individual and societal level.
Like quality of life, cognition is a fundamental component of 
health and well-being. However, as an outcome, cognition is over-
looked within current clinical trials where this is not a formal out-
come. Adverse event reporting suggests that medications are often 
implicated in a range of cognitive adverse effects but the association 
between these effects and formal measures of cognition is yet to be 
explored. It is suggested that cognition testing should be incorpo-
rated into a wide range of trials as standard, to ensure that both neg-
ative effects but also off-target beneficial effects to cognition can 
be evaluated. As per the cognitive footprint policy, this will ensure 
that cognition is prioritized within research but also that it is given 
due attention more downstream in policy-making and resource allo-
cation. This will help to ensure cognition is given every consideration 
by both clinical trialists and regulators.
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